181 related articles for article (PubMed ID: 15737239)
1. L-histidine inhibits production of lysophosphatidic acid by the tumor-associated cytokine, autotaxin.
Clair T; Koh E; Ptaszynska M; Bandle RW; Liotta LA; Schiffmann E; Stracke ML
Lipids Health Dis; 2005 Feb; 4():5. PubMed ID: 15737239
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and structure-activity relationships of tyrosine-based inhibitors of autotaxin (ATX).
East JE; Kennedy AJ; Tomsig JL; De Leon AR; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2010 Dec; 20(23):7132-6. PubMed ID: 20951039
[TBL] [Abstract][Full Text] [Related]
3. Enzymatic activation of autotaxin by divalent cations without EF-hand loop region involvement.
Lee J; Jung ID; Nam SW; Clair T; Jeong EM; Hong SY; Han JW; Lee HW; Stracke ML; Lee HY
Biochem Pharmacol; 2001 Jul; 62(2):219-24. PubMed ID: 11389881
[TBL] [Abstract][Full Text] [Related]
4. Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production.
Umezu-Goto M; Kishi Y; Taira A; Hama K; Dohmae N; Takio K; Yamori T; Mills GB; Inoue K; Aoki J; Arai H
J Cell Biol; 2002 Jul; 158(2):227-33. PubMed ID: 12119361
[TBL] [Abstract][Full Text] [Related]
5. Autotaxin: a protein with two faces.
Tania M; Khan MA; Zhang H; Li J; Song Y
Biochem Biophys Res Commun; 2010 Oct; 401(4):493-7. PubMed ID: 20888793
[TBL] [Abstract][Full Text] [Related]
6. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation.
Gierse J; Thorarensen A; Beltey K; Bradshaw-Pierce E; Cortes-Burgos L; Hall T; Johnston A; Murphy M; Nemirovskiy O; Ogawa S; Pegg L; Pelc M; Prinsen M; Schnute M; Wendling J; Wene S; Weinberg R; Wittwer A; Zweifel B; Masferrer J
J Pharmacol Exp Ther; 2010 Jul; 334(1):310-7. PubMed ID: 20392816
[TBL] [Abstract][Full Text] [Related]
7. Autotaxin (lysoPLD/NPP2) protects fibroblasts from apoptosis through its enzymatic product, lysophosphatidic acid, utilizing albumin-bound substrate.
Song J; Clair T; Noh JH; Eun JW; Ryu SY; Lee SN; Ahn YM; Kim SY; Lee SH; Park WS; Yoo NJ; Lee JY; Nam SW
Biochem Biophys Res Commun; 2005 Nov; 337(3):967-75. PubMed ID: 16219296
[TBL] [Abstract][Full Text] [Related]
8. Lysophosphatidic acid and autotaxin stimulate cell motility of neoplastic and non-neoplastic cells through LPA1.
Hama K; Aoki J; Fukaya M; Kishi Y; Sakai T; Suzuki R; Ohta H; Yamori T; Watanabe M; Chun J; Arai H
J Biol Chem; 2004 Apr; 279(17):17634-9. PubMed ID: 14744855
[TBL] [Abstract][Full Text] [Related]
9. Production of lysophosphatidic acid in blister fluid: involvement of a lysophospholipase D activity.
Mazereeuw-Hautier J; Gres S; Fanguin M; Cariven C; Fauvel J; Perret B; Chap H; Salles JP; Saulnier-Blache JS
J Invest Dermatol; 2005 Sep; 125(3):421-7. PubMed ID: 16117781
[TBL] [Abstract][Full Text] [Related]
10. Autotaxin and lysophosphatidic acid stimulate intestinal cell motility by redistribution of the actin modifying protein villin to the developing lamellipodia.
Khurana S; Tomar A; George SP; Wang Y; Siddiqui MR; Guo H; Tigyi G; Mathew S
Exp Cell Res; 2008 Feb; 314(3):530-42. PubMed ID: 18054784
[TBL] [Abstract][Full Text] [Related]
11. Regulation and biological activities of the autotaxin-LPA axis.
van Meeteren LA; Moolenaar WH
Prog Lipid Res; 2007 Mar; 46(2):145-60. PubMed ID: 17459484
[TBL] [Abstract][Full Text] [Related]
12. Submucosal connective tissue-type mast cells contribute to the production of lysophosphatidic acid (LPA) in the gastrointestinal tract through the secretion of autotaxin (ATX)/lysophospholipase D (lysoPLD).
Mori K; Kitayama J; Aoki J; Kishi Y; Shida D; Yamashita H; Arai H; Nagawa H
Virchows Arch; 2007 Jul; 451(1):47-56. PubMed ID: 17554559
[TBL] [Abstract][Full Text] [Related]
13. Novel point mutations attenuate autotaxin activity.
Koh E; Bandle RW; Roberts DD; Stracke ML; Clair T
Lipids Health Dis; 2009 Feb; 8():4. PubMed ID: 19222837
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and biological evaluation of phosphonate derivatives as autotaxin (ATX) inhibitors.
Cui P; Tomsig JL; McCalmont WF; Lee S; Becker CJ; Lynch KR; Macdonald TL
Bioorg Med Chem Lett; 2007 Mar; 17(6):1634-40. PubMed ID: 17257836
[TBL] [Abstract][Full Text] [Related]
15. Lysophospholipids in the limelight: autotaxin takes center stage.
Moolenaar WH
J Cell Biol; 2002 Jul; 158(2):197-9. PubMed ID: 12135981
[TBL] [Abstract][Full Text] [Related]
16. Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C.
Watanabe N; Ikeda H; Nakamura K; Ohkawa R; Kume Y; Aoki J; Hama K; Okudaira S; Tanaka M; Tomiya T; Yanase M; Tejima K; Nishikawa T; Arai M; Arai H; Omata M; Fujiwara K; Yatomi Y
J Clin Gastroenterol; 2007 Jul; 41(6):616-23. PubMed ID: 17577119
[TBL] [Abstract][Full Text] [Related]
17. Optimization of a pipemidic acid autotaxin inhibitor.
Hoeglund AB; Bostic HE; Howard AL; Wanjala IW; Best MD; Baker DL; Parrill AL
J Med Chem; 2010 Feb; 53(3):1056-66. PubMed ID: 20041668
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate.
van Meeteren LA; Ruurs P; Christodoulou E; Goding JW; Takakusa H; Kikuchi K; Perrakis A; Nagano T; Moolenaar WH
J Biol Chem; 2005 Jun; 280(22):21155-61. PubMed ID: 15769751
[TBL] [Abstract][Full Text] [Related]
19. Autotaxin, a secreted lysophospholipase D, is essential for blood vessel formation during development.
van Meeteren LA; Ruurs P; Stortelers C; Bouwman P; van Rooijen MA; Pradère JP; Pettit TR; Wakelam MJ; Saulnier-Blache JS; Mummery CL; Moolenaar WH; Jonkers J
Mol Cell Biol; 2006 Jul; 26(13):5015-22. PubMed ID: 16782887
[TBL] [Abstract][Full Text] [Related]
20. Site-directed mutations in the tumor-associated cytokine, autotaxin, eliminate nucleotide phosphodiesterase, lysophospholipase D, and motogenic activities.
Koh E; Clair T; Woodhouse EC; Schiffmann E; Liotta L; Stracke M
Cancer Res; 2003 May; 63(9):2042-5. PubMed ID: 12727817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
